Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Bavinger, Clay ^a   Bendavid, Eran ^a,b   Niehaus, Katherine ^a   Olshen, Richard A ^b   Olkin, Ingram ^a   Sundaram, Vandana ^a   Wein, Nicole ^a   Holodniy, Mark ^c   Hou, Nanjiang ^a,c   Owens, Douglas K ^a,c   Desai, Manisha ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; HUMANS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RISK;

EID: 84875435582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059551     Document Type: Article

References (53)

1. The Antiretroviral Therapy Cohort Collaboration, (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
2. The Antiretroviral Therapy Cohort Collaboration, (2010) Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 15: 1387-1396.
3. Grinspoon S, Carr A, (2005) Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. N Engl J Med 352: 48-62.
4. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371: 1417-1426.
5. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993-2003.
6. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, et al. (2010) Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201: 318-330.
7. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte AD, et al. (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356: 1723-1735.
8. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, et al. (2010) Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 170: 1228-1238.
9. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, et al. (2012) No Association of Abacavir Use with Myocardial Infarction: Findings of an FDA Meta-analysis. JAIDS Ahead of Print.
10. Ribaudo JH, Constance A Benson, Yu Zheng, Susan L Koletar, et al. (2011) No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT. Clin Infect Dis 52: 929-940.
11. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, et al. (2009) Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 51: 20-28.
12. Agency for Healthcare Research and Quality (2007) Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews. Available: http://effectivehealthcare.ahrq.gov/repFiles/2007_2010DraftMethodsGuide.pdf.
13. Jadad A, Moore RA, Carroll D, Jenkinson C, Ryeynolds DJ, et al. (1996) Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Control Clin Trials 17: 1-12.
14. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, et al. (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 7: 10.
15. Braga LH, Pemberton J, Demaria J, Lorenzo AJ, (2011) Methodological concerns and quality appraisal of contemporary systematic reviews and meta-analyses in pediatric urology. J Urol 186: 266-271.
16. Viechtbauer W (2010) Conducting Meta-Analyses in R with the metafor Package. J Stat Softw 36.
17. Fisher RA, (1948) Questions and Answers #14. The American Statistician 2: 30-31.
18. Fisher RA (1925) Statistical Methods for Research Workers. Edinburgh: Oliver and Boyd.
19. R Development Core Team (2011) R: A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing.
20. Coplan PM, Nikas A, Japour A, Cormier K, Maradit-Kremers H, et al. (2003) Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. Aids Res Hum Retroviruses 19(6): 449-455.
21. Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, et al. (2010) Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 11: 130-136.
22. Durand M, Sheehy O, Baril J-G, Lelorier J, Tremblay C, et al. (2009) Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec's public health insurance database (QPHID). 5th IAS Conference on HIV Pathogenesis and Treatment.
23. Daftary M, Dutta AP, Xue Z, Wyl Vv, Young M, et al. (2004) Women's Intragency HIV Study (WIHS): cardiovascular outcomes in women on PI therapy. The XV International AIDS Conference.
24. Holmberg SD, Moorman AC, Tong TC, Ward DJ, Wood KC, et al. (2002) Protease inhibitor drug use and adverse cardiovascular events in ambulatory HIV-infected patients. The XIV International AIDS Conference.
25. Rickerts V, Brodt H, Staszewski S, Stille W, (2000) Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 5: 329-333.
26. Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, et al. (2006) Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 20: 1941-1950.
27. Iloeje UH, Yuan Y, L'Italien G, Mauskopf J, Holmberg SD, et al. (2005) Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 6: 37-44.
28. Lundgren JD, Neuhaus J, Babiker A, Cooper D, Duprez D, et al. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22: F17-F24.
29. Bedimo R, A Westfall, H Drechsler, Tebas P (2009) Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. 5th IAS Conference on HIV Pathogenesis and Treatment.
30. Choi A, Vittinghoff E, Deeks SG, Weekleya C, Liaand Y, (2011) Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons AIDS. 25: 1289-1298.
31. Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, et al. (2010) Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Med 11: 554-564.
32. Martin A, Bloch M, Amin J, Baker D, Cooper DA, et al. (2009) Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial. Clin Infect Dis 49: 1591-1601.
33. Corral I, Quereda C, Moreno A, Perez-Elias MJ, Dronda F, et al. (2009) Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors. Cerebrovasc Dis 27: 559-563.
34. Levy AR, Sobolev B, Hogg RS, Iloeje U, Mukherjee J, et al. (2003) Risks of cardiovascular disease associated with highly active anti-retroviral therapy among persons treated for HIV/AIDS. The 2nd IAS Conference on HIV Pathogenesis and Treatment.
35. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA, (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348: 702-710.
36. David MH, Hornung R, Fichtenbaum CJ, (2002) Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 34: 98-102.
37. Vaughn G, Detels R, (2007) Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohort. AIDS Care 19: 492-499.
38. The Writing Committee of the D:A:D Study Group (2004) Cardio- and cerebrovascular events in HIV-infected persons. AIDS 18: 1811-1817.
39. Triant V, Regan S, Lee H, Sax P, Meigs J, Grinspoon S (2010) Association of antiretroviral therapy and HIV-related factors with acute myocardial infarction rates. International AIDS Conference. Vienna.
40. Quiros-Roldan E, Torti C, Tinelli C, Moretti F, Zanini B, et al. (2005) Risk factors for myocardial infarction in HIV-positive patients. Int J STD AIDS 16: 14-18.
41. Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, et al. (2003) An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 25: 2405-2418.
42. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S, (2002) Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 30: 471-477.
43. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P, (2011) Abacavir Use and Risk of Acute Myocardial Infarction and Cerebrovascular Events in the Highly Active Antiretroviral Therapy Era. Clin Infect Dis 53: 84-91.
44. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, et al. (2011) No Association of Myocardial Infarction with Abacavir Use: Findings of an FDA Meta-analysis. Conference on Retroviruses and Opportunistic Infections. Boston.
45. Robins JM, Hernán MA, Brumback B, (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560.
46. Hernán MA, Brumback B, Robins J, (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11: 561-570.
47. Hernán M, Brumback B, Robins JM, (2001) Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc 96: 440-448.
48. Hernán MA, Brumback B, Robins JM, (2002) Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 21: 1689-1709.
49. Sturmer T, Schneeweiss S, Avorn J, Glynn RJ, (2005) Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol 162(3): 279-289.
50. Joffe MM, Rosenbaum PR, (1999) Invited commentary: propensity scores. Am J Epidemiol 150: 327-33.
51. Hernan MA, Robins JM, (2006) Instruments for causal inference: an epidemiologist's dream? Epidemiology 17: 360-372.
52. Stürmer T, Schneeweiss S, Rothman KJ, Avorn J, Glynn RJ, (2007) Performance of propensity score calibration-a simulation study. Am J Epidemiol 165: 1110-1118.
53. Islam F, Wu J, Jansson J, Wilson D, (2012) Relative risk of cardiovascular disease among people living with HIV: a systemic review and meta-analysis. HIV Med 13(8): 453-68.